Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Aflibercept

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    147 result(s) found for: Aflibercept. Displaying page 4 of 8.
    « Previous 1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2014-002384-15 Sponsor Protocol Number: 3.0 Start Date*: 2014-10-23
    Sponsor Name:Universitätsklinik für Augenheilkunde und Optometrie
    Full Title: Intravitreal Aflibercept treatment in RAP-Lesions, PED, hemorrhagic CNV and PCV
    Medical condition: Exsudative Maculopathies
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10063381 Polypoidal choroidal vasculopathy PT
    17.0 10015919 - Eye disorders 10052501 Detachment of retinal pigment epithelium PT
    17.0 10015919 - Eye disorders 10069125 Retinal angiomatous proliferation LLT
    17.0 10015919 - Eye disorders 10060823 Choroidal neovascularisation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004608-78 Sponsor Protocol Number: LSFG-1.2 Start Date*: 2017-03-03
    Sponsor Name:Kepler University Hospital, Institute of Ophthalmology
    Full Title: The Effect of Intravitreal Aflibercept on Ocular Perfusion – a Pilot Study
    Medical condition: Exudative AMD
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004853 10025411 Macular degeneration senile LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005500-18 Sponsor Protocol Number: VITCLEAR Start Date*: 2013-11-18
    Sponsor Name:King's College Hospital NHS Foundation Trust [...]
    1. King's College Hospital NHS Foundation Trust
    2. King's College London
    Full Title: A pharmacokinetic study: ranibizumab, aflibercept and the effect of vitrectomy
    Medical condition: Age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10064930 Age-related macular degeneration PT
    17.0 10015919 - Eye disorders 10067791 Wet macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-001061-37 Sponsor Protocol Number: KS301P103 Start Date*: 2020-12-11
    Sponsor Name:Kodiak Sciences Inc.
    Full Title: A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal A...
    Medical condition: Macular edema secondary to retinal vein occlusion
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10067791 Wet macular degeneration LLT
    20.0 10015919 - Eye disorders 10015919 Eye disorders SOC
    20.0 10015919 - Eye disorders 10054467 Macular edema LLT
    20.1 10015919 - Eye disorders 10057934 Diabetic macular edema LLT
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Prematurely Ended) DE (Completed) SK (Prematurely Ended) CZ (Prematurely Ended) FR (Prematurely Ended) HU (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004278-23 Sponsor Protocol Number: CT-P42_3.1 Start Date*: 2021-03-16
    Sponsor Name:CELLTRION Inc.
    Full Title: A Randomized, Active-Controlled, Double-Masked, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P42 in Comparison with Eylea in Patients with Diabetic Macular Edema
    Medical condition: Diabetic Macular Edema
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SK (Completed) HU (Completed) CZ (Completed) PL (Completed) LT (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2008-004178-41 Sponsor Protocol Number: EFC10668 Start Date*: 2008-12-15
    Sponsor Name:sanofi-aventis recherche et développement
    Full Title: Randomized, Multinational, Study Of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer
    Medical condition: metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-001640-38 Sponsor Protocol Number: ATTRACT Start Date*: 2014-08-08
    Sponsor Name:CHU DE POITIERS
    Full Title: Efficacy of Aflibercept (Eylea®) on Type 3 choroidal neovascularization.
    Medical condition: Retinal diseases (type 3 choroidal neovascularization)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004853 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002124-17 Sponsor Protocol Number: IMO-AFLI-2013-01 Start Date*: 2013-10-04
    Sponsor Name:Fundació de Recerca de L?Institut de Microcirurgia Ocular
    Full Title: Phase IV study to evaluate genetic variants of VEGF pathway as biomarkers of VEGF Trap-Eye treatment efficacy in subjects with neovascular age-related macular degeneration (wAMD).
    Medical condition: Wet age-related macular degeneration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-000959-24 Sponsor Protocol Number: DMOE-001-10 Start Date*: 2015-08-10
    Sponsor Name:Abteilung für Augenheilkunde, AKH Linz
    Full Title: Clinical characterization of the treatment of diabetic macular edema with aflibercept in an outpatient setting by evaluation of a regional network of ophthalmologic care givers
    Medical condition: Diabetic Retinopathy and diabetic macular edema are leading causes for visual loss and blindness in young adults around the world.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001058-73 Sponsor Protocol Number: BEY-RAP.V1.0 Start Date*: 2021-06-23
    Sponsor Name:Fakultní nemocnice Královské Vinohrady
    Full Title: Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation - Prospective Randomised Study
    Medical condition: Retinal angiomatous proliferation form of neovascular age related macular degeneration (AMD).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-000986-30 Sponsor Protocol Number: 140109 Start Date*: 2015-03-03
    Sponsor Name:IRCCS Ospedale San Raffaele U.O. Oculistica
    Full Title: Intravitreal Aflibercept for Choroidal Neovascularization Secondary to Angioid Streaks (EYLEA-STRIE)
    Medical condition: Choroidal neovascularization secondary to angioid streaks .
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004853 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004358-40 Sponsor Protocol Number: MYL-1701P-3001 Start Date*: 2018-11-02
    Sponsor Name:Mylan Inc
    Full Title: A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects with Diabetic Macular Edema
    Medical condition: Diabetic macular edema
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2015-003162-82 Sponsor Protocol Number: 00171 Start Date*: 2015-10-21
    Sponsor Name:Raimo Tuuminen
    Full Title: treat-and-extend regimen (TER) in patients with diabetic macular edema
    Medical condition: Diabetic macular edema
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001508-45 Sponsor Protocol Number: TTD-16-02 Start Date*: 2016-09-19
    Sponsor Name:Grupo de Tratamiento de los Tumores Digestivos (TTD)
    Full Title: Phase II clinical trial to evaluate the efficacy of FOLFIRI + aflibercept in patients with metastatic colorectal cancer previously treated with oxaliplatin with or without ACE polymorphisms
    Medical condition: Metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-004076-21 Sponsor Protocol Number: TTD-16-03 Start Date*: 2017-05-30
    Sponsor Name:Grupo de Tratamiento de los Tumores Digestivos (TTD)
    Full Title: Randomised, multicentre, phase II pilot study to assess the efficacy and safety of treatment with FOLFIRI-aflibercept compared to initial treatment with FOLFIRI-aflibercept (for 6 cycles) followed ...
    Medical condition: Metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-006796-80 Sponsor Protocol Number: TES10897 Start Date*: 2009-04-23
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: The QUTIE Study: A Randomized, Double-Blind, Placebo-controlled Study Comparing Aflibercept Versus Placebo on the QTc interval in Cancer Patients treated with Docetaxel
    Medical condition: Cancer
    Disease: Version SOC Term Classification Code Term Level
    11.0 10007050 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003661-18 Sponsor Protocol Number: 2014-878 Start Date*: 2015-09-29
    Sponsor Name:Hospices Civils de Lyon
    Full Title: Phase II study evaluating the efficacy of aflibercept for the treatment of choroidal neovascularization complicating angioid streaks in young subjects: the ASTRID study
    Medical condition: choroidal neovascularization complicating angioid streaks
    Disease: Version SOC Term Classification Code Term Level
    18.0 10015919 - Eye disorders 10060823 Choroidal neovascularisation PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-002308-15 Sponsor Protocol Number: PR001 Start Date*: 2013-11-11
    Sponsor Name:Guys & St. Thomas' NHS Foundation Trust
    Full Title: A phase I/II dose finding study evaluating the safety and tolerability of CAPecitabine and AflIbercept in patients with unresectable metasTAtic colorectaL cancer deemed unsuitable for doublet/ trip...
    Medical condition: Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-002302-36 Sponsor Protocol Number: MATE2015 Start Date*: 2018-02-06
    Sponsor Name:York Teaching Hospital
    Full Title: Treating neovascular age-related Macular Degeneration with Aflibercept:A multi-centre randomized controlled trial comparing Standard Care with an individualised Treat and Extend regimen.
    Medical condition: Neovascular Age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10064930 Age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2019-003883-28 Sponsor Protocol Number: SB15-3001 Start Date*: 2020-05-28
    Sponsor Name:Samsung Bioepis Co., Ltd.
    Full Title: A Phase III Randomised, Double-masked, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity between SB15 (proposed aflibercept biosimilar) and Eyl...
    Medical condition: Neovascular age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) CZ (Completed) HU (Completed) HR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 07:56:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA